Exagen Diagnostics
Helps patients and healthcare providers in the diagnosis, prognosis, and management of autoimmune conditions.
Launch date
Employees
Market cap
$51.5m
Enterprise valuation
$51m (Public information from Sep 2024)
Share price
$3.1 XGN
Albuquerque New Mexico (HQ)
Financials
Estimates*
USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|---|---|
Revenues | 40.4m | 42.0m | 48.3m | 45.6m | 52.5m | 57.2m | 65.0m |
% growth | 24 % | 4 % | 15 % | (6 %) | 15 % | 9 % | 14 % |
EBITDA | (8.8m) | (14.2m) | (24.1m) | (39.7m) | (19.2m) | - | - |
% EBITDA margin | (22 %) | (34 %) | (50 %) | (87 %) | (36 %) | - | - |
Profit | (12.0m) | (16.7m) | (26.9m) | (47.4m) | (23.7m) | - | - |
% profit margin | (30 %) | (40 %) | (56 %) | (104 %) | (45 %) | - | - |
R&D budget | 2.2m | 3.6m | 7.2m | 9.9m | 4.9m | - | - |
R&D % of revenue | 5 % | 9 % | 15 % | 22 % | 9 % | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$5.4m | Series A | ||
$7.0m | Series B | ||
N/A | $1.0m | Early VC | |
$12.0m | Early VC | ||
$16.9m | Early VC | ||
$5.4m | Early VC | ||
N/A | $4.9m | Early VC | |
N/A | $1.0m | Debt | |
$5.3m | Series C | ||
N/A | $123k | Debt | |
N/A | $5.0m | Early VC | |
$25.0m | Debt | ||
$4.0m | Debt | ||
N/A | $1.8m | Debt | |
N/A | $3.0m | Debt | |
N/A | $16.8m | Series E | |
N/A | $2.1m | Debt | |
$25.0m | Debt | ||
N/A | $23.0m | Series F | |
N/A | $6.6m | Late VC | |
$22.6m | Late VC | ||
N/A | N/A | IPO | |
$27.2m | Post IPO Debt | ||
Total Funding | $132m |
Recent News about Exagen Diagnostics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.